I thank van Balveren and colleagues for their insightful response to my editorial regarding the use of clinical and laboratory data warehouses to answer questions that directly impact current patients and identify patterns that could lead to further research and updates to patient care. The authors describe three pitfalls in the analysis of such data and recommend caution in their use. While I agree with much of their conclusions, the recent COVID-19 pandemic has laid bare the limitations of keeping large-scale laboratory data out of the hands of laboratory experts, hospital strategic command centers, and even clinicians on the front lines. I believe that the pandemic serves as an excellent example of the need for rapid access to "good enough" data when "perfect" data are currently unavailable.

The first pitfall described was the risk of inclusion bias, such that missing data may not represent the full spectrum of patients under consideration. This is definitely the case with COVID-19 testing shortages, where hospitals must develop strict testing criteria to ration available laboratory resources and collection swabs. As a result, the positivity rate of the test at any particular institution likely does not reflect the true prevalence of the disease in the region. To address this, our institution uses statistical techniques to extrapolate "best" and "worst" case scenarios and collects data on both patients who received COVID-19 testing, as well as patient populations where testing has been requested but not performed. When a request is made to expand testing criteria in a particular population, we can quickly search for similar patients who were tested to estimate the impact and utility of expanded testing.

The second pitfall described was the lack of uniformity in retrospectively collected data. Again, we see this during the current crisis, since patients are being tested at different points in their clinical course. However, this limitation opens up another avenue of exploration: the utility of repeat testing. We can quickly pull data on patients who received more than one COVID-19 test to infer the rationale of the providers' real-world testing decisions, as well as to potentially predict the likelihood that a patient who initially tested negative may later test positive. Such results could impact future development of testing criteria.

The third pitfall described was the lack of synchronization of data sources. I know this all too well, observing how quickly COVID-19 tests with different methodologies from different laboratories had to be brought into immediate use to facilitate the rising demand for testing. To address this, information services must make rapid and transparent decisions about which test results can be aggregated in order to balance consistency in data analysis with the risk of introducing unexpected biases. For example, while we allow ambulatory clinics to enter COVID-19 test results into the electronic health record that were transcribed from external laboratory reports, we do not include those results in our data for analysis, since the provenance of such data has not been validated.

At my institution, which performs COVID-19 testing for 13 hospitals and numerous ambulatory clinics, we recognized the need to organize the somewhat fragmented reporting of laboratory test results for better visualization and analysis. This has led to the development of dashboards that track test results by date, location, and test device for rapid retrieval of important conclusions that drive strategic decisions during the COVID-19 crisis. We have also leveraged data analytic tools within the commercial electronic health record used at our institution to tie clinical data to the laboratory data. I recognize the limitations thoughtfully provided by van Balveren and colleagues, but I also argue that, by implementing maximal safeguards to data integrity, sensitivity analysis, and rapid validation of existing data, we can still make well-informed decisions to impact our patient population during a clinical crisis.
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